IGF2BP2 and hepatocellular carcinoma: In a prospective multicenter study including 160 patients carrying hepatocarcinoma (HCC) and 74 healthy controls, the diagnostic potential of a panel of six auto-antibodies against Sui1, p62, RalA, p53, NY-ESO-1, and c-Myc antigens was tested [50].